<?xml version="1.0" encoding="UTF-8"?>
<results title="country">
 <result pre="D.123SmithSuzanne1GideonClare1BonomoRobert A.1234Falck-YtterYngve1234*[1], Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio," exact="United States" post="of America[2], University Hospitals Case Medical Center, Cleveland, Ohio,"/>
 <result pre="States of America[2], University Hospitals Case Medical Center, Cleveland, Ohio," exact="United States" post="of America[3], Case Western Reserve University, Cleveland, Ohio, United"/>
 <result pre="United States of America[3], Case Western Reserve University, Cleveland, Ohio," exact="United States" post="of America[4], Geriatric Research Education and Clinical Center (GRECC),"/>
 <result pre="Center (GRECC), Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio," exact="United States" post="of AmericaKimDo YoungEditor[], Yonsei University College of Medicine, REPUBLIC"/>
 <result pre="are infected with the Hepatitis C virus (HCV).[1, 2] In" exact="the United States," post="between 2.7 and 3.5 million people are believed to"/>
 <result pre="infected with the Hepatitis C virus (HCV).[1, 2] In the" exact="United States," post="between 2.7 and 3.5 million people are believed to"/>
 <result pre="be infected with HCV.[3, 4] Approximately 5.4% of veterans in" exact="the United States" post="have chronic HCV, which is more than double the"/>
 <result pre="infected with HCV.[3, 4] Approximately 5.4% of veterans in the" exact="United States" post="have chronic HCV, which is more than double the"/>
 <result pre="nonstructural 3/4A protease inhibitors, boceprevir and telaprevir, were approved by" exact="the United States" post="Food and Drug Administration (FDA) in 2011 for the"/>
 <result pre="3/4A protease inhibitors, boceprevir and telaprevir, were approved by the" exact="United States" post="Food and Drug Administration (FDA) in 2011 for the"/>
 <result pre="KuhnertWL, AlterMJ. The prevalence of hepatitis C virus infection in" exact="the United States," post="1999 through 2002. Annals of internal medicine. 2006;144(10):705–14. .16702586"/>
 <result pre="AlterMJ. The prevalence of hepatitis C virus infection in the" exact="United States," post="1999 through 2002. Annals of internal medicine. 2006;144(10):705–14. .16702586"/>
 <result pre="KlevensRM, WardJW, McQuillanGM, et al.Chronic hepatitis C virus infection in" exact="the United States," post="National Health and Nutrition Examination Survey 2003 to 2010."/>
 <result pre="WardJW, McQuillanGM, et al.Chronic hepatitis C virus infection in the" exact="United States," post="National Health and Nutrition Examination Survey 2003 to 2010."/>
 <result pre="et al.Elevated prevalence of hepatitis C infection in users of" exact="United States" post="veterans medical centers. Hepatology. 2005;41(1):88–96. 10.1002/hep.20502 .15619249 6PradatP, VoirinN,"/>
 <result pre="hepatocellular carcinoma. Proceedings of the National Academy of Sciences of" exact="the United States" post="of America. 1990;87(17):6547–9. 2168552 8SmithBD, MorganRL, BeckettGA, Falck-YtterY, HoltzmanD,"/>
 <result pre="carcinoma. Proceedings of the National Academy of Sciences of the" exact="United States of America." post="1990;87(17):6547–9. 2168552 8SmithBD, MorganRL, BeckettGA, Falck-YtterY, HoltzmanD, TeoCG, et"/>
 <result pre="of hepatitis C virus treatment with sofosbuvir and ledipasvir in" exact="the United States." post="Ann Intern Med. 2015;162(6):397–406. 10.7326/M14-133625775312 32BackusLI, BelperioPS, ShahoumianTA, LoomisTP,"/>
 <result pre="hepatitis C virus treatment with sofosbuvir and ledipasvir in the" exact="United States." post="Ann Intern Med. 2015;162(6):397–406. 10.7326/M14-133625775312 32BackusLI, BelperioPS, ShahoumianTA, LoomisTP,"/>
</results>
